ArticleJournal of translational medicine2019
Large-scale expansion and characterization of CD3
Article in Journal of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- The manufacture of AAV for gene therapy applications using a closed, semi-automated hollow-fiber bioreactor.Molecular therapy. Methods & clinical development · 2025Article
- Transition from manual to automated processes for autologous T cell therapy manufacturing using bioreactor with expandable culture area.Scientific reports · 2025Article
- Automated, aseptic sampling with small-volume capacity from microbioreactors for cell therapy process analysis.Frontiers in bioengineering and biotechnology · 2025Article
- Optimising and adapting perfusion feeds in serum-free medium to intensify CAR-T cell expansion in stirred-tank bioreactors.Frontiers in bioengineering and biotechnology · 2025Article
- A high-density microfluidic bioreactor for the automated manufacturing of CAR T cells.Nature biomedical engineering · 2024Article
- Deletion of CD38 enhances CD19 chimeric antigen receptor T cell function.Molecular therapy. Oncology · 2024Article
- Impact of serum‑free media on the expansion and functionality of CD19.CAR T‑cells.International journal of molecular medicine · 2023Article
- An optimized HEK293T cell expansion protocol using a hollow-fiber bioreactor system.Biology methods & protocols · 2023Article
- Recent Advances in the Development of Bioreactors for Manufacturing of Adoptive Cell Immunotherapies.Bioengineering (Basel, Switzerland) · 2022Review
- Membrane Applications in Autologous Cell Therapy.Membranes · 2022Review
- Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapies.International reviews of immunology · 2022Article
- Impact of Manufacturing Procedures on CAR T Cell Functionality.Frontiers in immunology · 2022Review
- Enabling Allogeneic T Cell-Based Therapies: Scalable Stirred-Tank Bioreactor Mediated Manufacturing.Frontiers in medical technology · 2022Article
- Influence of Culture Conditions on Ex Vivo Expansion of T Lymphocytes and Their Function for Therapy: Current Insights and Open Questions.Frontiers in bioengineering and biotechnology · 2022Review
- Optimization of Culture Media forAdvanced biomedical research · 2022Article
- Review
- Scalable Manufacturing of CAR T cells for Cancer Immunotherapy.Blood cancer discovery · 2021Review
- Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy.Journal of biological engineering · 2021Review
- Manufacturing T cells in hollow fiber membrane bioreactors changes their programming and enhances their potency.Oncoimmunology · 2021Article
- CAR T-Cell Production Using Nonviral Approaches.Journal of immunology research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe rapid evolution of cell-based immunotherapies such as chimeric antigen receptor T-cells for treatment of hematological cancers has precipitated the need for a platform to expand these cells ex vivo in a safe, efficient, and reproducible manner. In the Quantum
methodsMononuclear cells from leukapheresis products from 5 healthy donors were activated with anti-CD3/CD28 Dynabeads
resultsFrom starting products of 30 or 85 × 10
conclusionsThe Quantum system has been successfully used to produce large quantities of functional T-cells at clinical dosing scale and within a short timeframe. This platform could have wide applicability for autologous and allogeneic cellular immunotherapies for the treatment of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.